Wrocław, 11/03/2021

Press release for immediate release

Genomtec to accelerate commercialization of Genomtec®ID

Wroclaw, Poland - November 3, 2021. - Genomtec S.A. "GMT", a NewConnect-listed medical technology company, started today the analysis to accelerate the planned commercialization of the Genomtec®ID platform. The analysis will include the selection of solutions to support the company's strategic development, primarily in terms of determining the optimal time to market with the Genomtec®ID solution, including its acceleration compared to the currently announced plan.

The analysis will take into account various scenarios to accelerate the Company's growth, including, but not limited to, the potential possible use of regulations to enable faster certification of the device, and thus faster commercialization in the marketplace.

"We expect the transitional provisions of the IVD regulation (IVDR) to be extended, which would give us the opportunity to register Genomtec®ID as an IVD device in the European Union earlier under the current Directive (IVDD), thus allowing us to start the commercialization process of our mobile POCT platform for genetic testing," - said Miron Tokarski, CEO and co-founder of Genomtec SA.

One of the analysed options will be the optimal start of Genomtec®ID sales by the Company through commercial partners and defining the right moment for commercialization by licensing or selling the technology.

Genomtec's current actions are aimed at accelerating the growth of the Company's product development efforts, scaling up operations and taking advantage of the current state of market attractiveness and regulatory conditions to bring our innovation sooner to the healthcare industry.

#####

Additional information at:

Genomtec S.A.
Magdalena Kicińska
+48 604 201 230
m.kicinska@genomtec.com

About Genomtec:

Genomtec is an innovative medical technology company dedicated to the development and commercialization of a mobile molecular diagnostics platform for detection of various infectious diseases, and also rapid laboratory diagnostic tests used, among others, in the detection of COVID-19 disease caused by the SARS-CoV-2 virus.

The company's flagship project is the Genomtec ID mobile IVD platform. The analyser is uniquely placed among Point-Of-Care (POC) products worldwide. It will allow for a quick and precise clinical molecular analysis outside the standard laboratory setting, without the need to involve qualified laboratory personnel. The system uses microfluidic technology and the

proprietary, patent protected SNAAT® isothermal technology. Appropriate design of the system enables the process to be carried out in record time, i.e. even in 15 minutes, with the diagnostic parameters equal to, and in some cases exceeding, the quality of PCR laboratory tests.

The development and manufacturing process is executed in close cooperation with international CMO (Contract Manufacturing Organization) companies. According to the assumptions of the Genomtec Management Board, the commercialization of the flagship solution will take place in the first half of 2022.

Manufacturing of Genomtec® SARS-CoV-2 EvaGreen® laboratory tests in RT-LAMP technology is based in Poland, with current EU market authorisation (CE-IVD), and product registration started in other regulatory jurisdictions outside Europe.

Genomtec was founded in 2016. Genomtec SA is headquartered in Wroclaw.

More information at: www.genomtec.com